Dr. Andrew Gaffney is Vice President, iPSC Platform at STEMCELL Technologies. In this episode, he discusses how his team is advancing pluripotent stem cell applications through high-quality iPSC line development, gene editing, organoid production, and GMP manufacturing for translational and clinical use. He also highlights key challenges in the field, including reproducibility, standardization, genetic diversity, and freedom-to-operate considerations, and explains how these factors impact the path from basic research to commercialization.

Transgene-Free Gastrulation Model – Scientists have produced a transgene-free stem cell model that recreates key features of human peri-gastrulation, including germ layer formation and early hematopoiesis.

Engineering Antibody-Producing Stem Cells – CRISPR-edited hematopoietic stem cells generate B cells that produce durable, protective antibodies following vaccination.

Safeguarding Chemical Reprogramming – Investigators have found that p53 is required for efficient chemical reprogramming by maintaining genomic stability and regulating early cell state transitions.

Targeting Barriers to Cardiac Repair – Knockdown of calreticulin enhances cardiac reprogramming and improves heart repair after injury.

Photo Reference: Courtesy of Dr. Andrew Gaffney

Never miss updates about new episodes.